The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Genetics and drug discovery had its origins in the 1980s with the development of positional cloning technology—that is, using genetic markers to map and identify the genes responsible for Mendelian ...

Targeted rewriting of the epigenome promises to overcome several challenges in direct gene editing in patient therapies.

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

CRISPR gene editing shows potential for treating genetic diseases. Explore how it may impact Down syndrome treatment and ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

While Rosie O’Donnell, 63, made a name for herself as a Broadway star and host of the Emmy-winning talk show The Rosie ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot ...

Coronary heart disease (CHD), characterized by atherosclerosis-induced myocardial ischemia, remains a leading cause of mortality in China. Safflower ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.